Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy

References

• Fisher, R.I. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma", New England Journal of Medicine 328, 1002–1006.
   PubMed Web of Science ®Google Scholar
• Coiffier, B., Feline, C.. Hemline, 0., et al. (2001) "Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study", Blood 98, Abstract #3025.
   Google Scholar
• Epelbaum, R.. Haim, N.. Ben-Shahar, M., et al. (1988) "Dose intensity of CHOP chemotherapy in diffuse aggressive large cell lymphoma", Israel Journal of Medical Sciences 24, 533-538_
   Google Scholar
• Kwak, LW., Halper, J., Olshen, RA., et al. (1990) "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis", Journal of Clinical Oncology 8, 963–977.
   PubMed Web of Science ®Google Scholar
• Morrison, V., Picozzi, V., Scott. S., et al. (2001) "The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade Non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis", Clinical Lymphoma 2, 47–56.
   PubMedGoogle Scholar
• Weiner, N., Fridman, M., Steinberg, D., et al. (1998) "A model to predict chemotherapy related neutropenic events in intermediate and high grade lymphoma (IHL) patients", Blood 92, Abstract #361.
   Google Scholar
• Lyman, G.. Dale, D., Crawfold, J., et al. (2001) "Risk of febrile neutropenia among patients receiving CHOP chemotherapy", Blood 98, Abstract #4642.
   Google Scholar
• Intragumtornchai, R., Sutheesophon. T., Sutcharitchan, P., et al. (2000) "A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive Non-Hodgkin's lymphoma", Leukemia and Lymphoma 37, 351–360.
   PubMed Web of Science ®Google Scholar
• Gomez, IL, Hidalgo, M., Casanova, L., et al. (1998) "Risk factors for treatment-related death in elderly patients with aggressive Nan-Hodgkin's lymphoma: results of a multivariate analysis", Journal of Clinical Oncology 16, 2065–2069.
   PubMed Web of Science ®Google Scholar
• Crawford, J., Ozer, H., Stoller, R., et al. (1991) "Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer", New England Journal of Medicine 325, 164–170.
   PubMed Web of Science ®Google Scholar
• Holmes, EA., O'Shaughnessy, J.A., Vukelja, S., et al. (2002) "Blinded, randomized. multicenter study to evaluate single adminis-tration pegftlgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage II/IV breast cancer", Journal of Clinical Oncology 20, 727–731.
   PubMed Web of Science ®Google Scholar
• Charlson, M.E. (1987) "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", Journal of Chronic Disease 40, 373–383.
   PubMedGoogle Scholar
• Deyo, R.A., Cherkin, D.C. and Ciol, M.A. (1993) "Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives". Journal of Clinical Epidemiology 46, 1075–1079.
   PubMed Web of Science ®Google Scholar
• Romano, P.S., Roos, L.L. and kills, J.G. (1993) "Adapting a clinical comorbidity index for use with ICD-9-CM administrative data; differing perspectives", Journal of Clinical Epidemiology 46, 1075–1079.
   PubMed Web of Science ®Google Scholar
• Carbone, P.P., Kaplan, H., Musshoff, K., et al. (1971) "Report of the committee on Hodgkin's disease staging classification", Cancer Research 31, 1860–1861.
   PubMed Web of Science ®Google Scholar
• (1982) "National Cancer Institute sponsored study of classifi-cations of Non-Hodgkin's lymphomas: summary and descrip-tion of a working formulation for clinical usage". Cancer 9, 2112–2135.
   Google Scholar
• Hryniuk, W. and Bush, H. (1984) "The importance of dose intensity in chemotherapy of metastatic breast cancer", Journal of Clinical Oncology 2, 1281–1288.
   PubMed Web of Science ®Google Scholar
• Kaplan, EL. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", Journal of the American Statistical Association 53, 457–481.
   Web of Science ®Google Scholar
• Peto, R. and Peto, J. (1972) "Asymptotically efficient rank invariant test procedures (with discussion)", Journal of the Royal Slatistical Society A 135, 185–206.
   Web of Science ®Google Scholar
• Cox, D.R. and Oakes, D. (1988) Analysis of Survival Data (Chapman and Hall. New York).
   Google Scholar
• Silber, J.H., Fridman, M. and DiPaola, R.S. (1998) "First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy", Journal of Clinical Oncology 16, 2392–2400.
   PubMed Web of Science ®Google Scholar
• Thomas, E.S., Rivera, EM., Erder, H.M., et aL (2001) "Using first cycle nadir absolute neutrophil count (FCNANC) as a risk factor for neutropenic events: a validation study", Proceedings of the American Society of Clinical Oncology 20, Abstract # I 44.
   Google Scholar
• Dixon. D.O., Neilan, B., Jones, S.E., et al. (1986) "Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma, The Southwest Oncology Group Experience", Journal of Clinical Oncology 4, 295–305.
   PubMed Web of Science ®Google Scholar
• Lyman, G.H., Kuderer, N.M. and Djulbegovic, B. (2002) "Prophylactic granulocyte colony-stimulating factor in patients receiving dose intensive cancer chemotherapy: a meta-analysis", American Journal of Medicine 112, 406–411.
   PubMed Web of Science ®Google Scholar